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A B S T R A C T
The cestode E. multilocularis causes the disease alveolar echinococcosis (AE) in humans. The continuously pro-
liferating metacestode (larval stage) of the parasite infects mostly the liver and exhibits tumor-like growth.
Current chemotherapeutical treatment options rely on benzimidazoles, which are rarely curative and have to be
applied daily and life-long. This can result in considerable hepatotoxicity and thus treatment discontinuation.
Therefore, novel drugs against AE are urgently needed. The anti-malarial meﬂoquine was previously shown to be
active against E. multilocularis metacestodes in vitro, and in mice infected by intraperitoneal inoculation of
metacestodes when administered at 100mg/kg by oral gavage twice a week for 12 weeks. In the present study,
the same dosage regime was applied in mice infected via oral uptake of eggs representing the natural route of
infection. After 12 weeks of treatment, the presence of parasite lesions was assessed in a liver squeeze chamber
and by PCR, and a signiﬁcantly reduced parasite load was found in meﬂoquine-treated animals. Assessment of
meﬂoquine plasma concentrations by HPLC and modeling using a two-compartment pharmacokinetic model
with ﬁrst-order absorption showed that> 90% of the expected steady-state levels (Cmin 1.15mg/L, Cmax
2.63 mg/L) were reached. These levels are close to concentrations achieved in humans during long-term weekly
dosage of 250mg (dose applied for malaria prophylaxis). In vitro structure-activity relationship analysis of
meﬂoquine and ten derivatives revealed that none of the derivatives exhibited stronger activities than me-
ﬂoquine. Activity was only observed, when the 2-piperidylmethanol group of meﬂoquine was replaced by an
amino group-containing residue and when the triﬂuoromethyl residue on position 8 of the quinoline structure
was present. This is in line with the anti-malarial activity of meﬂoquine and it implies that the mode of action in
E. multilocularis might be similar to the one against malaria.
1. Introduction
The parasitic cestode Echinococcus multilocularis causes alveolar
echinococcosis (AE) in humans and a variety of mammals, such as dogs,
captive monkeys, beavers, and others (Deplazes and Eckert, 2001). E.
multilocularis is found on the Northern hemisphere, including high en-
demicity areas in Central and Eastern Asia (e.g. Kyrgyzstan, China, and
Northern Japan) as well as in Central and Eastern Europe (Deplazes
et al., 2017). The total global burden of human AE was estimated to be
18′235 new cases per year (Torgerson et al., 2010). Over the recent
decades, the parasite became more prevalent in Europe (Thompson
et al., 2017) and Canada (Trotz-Williams et al., 2017). Especially in
endemic areas with low standard health care systems, the disease poses
an increasing and uncontrolled health problem (Kern et al., 2017).
Deﬁnitive hosts (mainly foxes, dogs, and raccoon dogs) harbor the
adult stage of E. multilocularis in their intestines and this leads to con-
tamination of the environment with infectious eggs. Intermediate hosts
such as small rodents, but also humans (dead-end hosts), and other
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mammals, may accidentally acquire eggs containing an infectious on-
cosphere orally, and be infected with the parasite. Following infection,
the oncosphere diﬀerentiates into the metacestode stage, primarily in
the liver, where it inﬁltrates the adjacent tissue by asexual proliferation
of vesicles. Metacestodes exhibit an unlimited reproductive potential,
gradually forming cancer-like lumps, often with necrotic areas in the
centre. Thus, human AE is a chronic disease with extensive morbidity
and mortality if untreated (Kern et al., 2017). The only curative treat-
ment for AE is complete surgical resection of the parasite tissue. Such
invasive surgery is performed in about 30% of all AE patients, therefore
most receive only continuous medication with the benzimidazole-de-
rivatives albendazole (ABZ) or mebendazole (Kern et al., 2017). Ben-
zimidazoles have drastically improved the life expectancy and quality
of life of patients. Whereas the 10-years survival rate of untreated AE
patients was 0–25% in the pre-benzimidazole era, benzimidazole-
treated patients to date have a 10-years survival rate of 91–97% in
countries with well-developed health-care (Ammann and Eckert, 1996;
Grüner et al., 2017). However, benzimidazoles are mainly parasito-
static, requiring life-long administration to avoid recurrence. Benzimi-
dazoles bind to beta tubulin and interfere in microtubule formation,
thereby impairing uptake of nutrients and parasite growth (Lacey,
1990). However, stem cells in the germinal layer of E. multilocularis
metacestodes express a beta tubulin isoform, TUB-2, which does not
bind to benzimidazoles rendering stem cells largely resistant to the
dosages of benzimidazoles used in standard treatments. This, in com-
bination with the limited uptake and half-life of the drug, could, at least
partially, explain the parasitostatic rather than parasiticidal action of
benzimidazoles (Brehm and Koziol, 2014). A drawback of benzimida-
zole-based therapy is that about 16% of the treated patients experience
adverse eﬀects such as hepatotoxicity that lead to treatment-dis-
continuation (Steiger et al., 1990). ABZ treatment increases the host
immune response against the parasite, implying that the action of
benzimidazoles could also be dependent on the immune system (Ricken
et al., 2017). With increasing numbers of patients and no alternative to
benzimidazoles, the development of better and/or alternative treatment
options becomes increasingly urgent (Kern et al., 2017). Two drugs that
were studied in clinical trials against AE over the last years are the anti-
fungal agent amphotericin B and the broad-spectrum anti-parasitic ni-
tazoxanide, but they were not further pursued due to minimal activity
in humans and pronounced side-eﬀects (Kern et al., 2008; Tappe et al.,
2009).
Pharmaceutical companies are reluctant to engage in preclinical
drug development for AE, and therefore an important focus is on re-
purposing of existing drugs or compound classes that are on the market
or being developed for other indications. This approach could result in
lower costs, lower risk of failure, and faster time to the market within
the drug development process (Andrews et al., 2014; Panic et al., 2014).
A rich source for drug repurposing against parasites are anti-malarials,
since over 6 million compounds have been screened for activity against
the blood stage of P. falciparum, and over 20′000 hits with activity in
the low μM range have been identiﬁed. Over the past years, several
anti-malarials were shown to exhibit activity against E. multilocularis
metacestodes (Lubinsky, 1969; Reuter et al., 2006; Spicher et al., 2008;
Küster et al., 2014; Stadelmann et al., 2016), including meﬂoquine
(Küster et al., 2011, 2015; Stadelmann et al., 2011). In Plasmodium,
meﬂoquine inhibits the formation of hemozoin, an essential step in
heme detoxiﬁcation upon hemoglobin degradation (Egan et al., 1994).
Additional proposed targets are the ribosomes (Wong et al., 2017),
phosphatidylinositol, volume-regulated anion channels and endocytosis
(Dassonville-Klimpt et al., 2011). Meﬂoquine is also active against the
helminth parasite Schistosoma (Keiser and Utzinger, 2012), where in-
hibition of hemozoin formation (Corrêa Soares et al., 2009) as well as
impairment of enolase activity (Manneck et al., 2012) were postulated
as potential mechanisms of action. In addition, meﬂoquine is active
against cancer cells (Sharma et al., 2012; Liu et al., 2016), and neuronal
cells (Lim and Go, 1985; Cruikshank et al., 2004; McArdle et al., 2005;
Milatovic et al., 2011). The adverse-eﬀects of meﬂoquine are well-
known. Meﬂoquine has been reported to induce a post-hepatic syn-
drome (including gastrointestinal disturbances, headache, malaise)
(Mawson, 2013) and may induce neuropsychiatric side-eﬀects in pa-
tients, who are either receiving malaria prophylaxis or single dose
treatment (Croft and Herxheimer, 2002; Croft, 2007; Grabias and
Kumar, 2016; Nevin and Byrd, 2016).
Upon in vitro treatment of E. multilocularis metacestodes with me-
ﬂoquine, a rapid separation of the cellular germinal layer from the
acellular laminated layer and collapse of the metacestode tissue was
observed (Küster et al., 2011). Subsequent injection of in vitro-treated
parasites into animals showed that the drug exhibited parasiticidal
activity (Küster et al., 2011). To reduce the expected neurological side-
eﬀects in vivo, erythro-enantiomers of meﬂoquine were tested in vitro, as
it was suggested that adverse eﬀects might be attributable mainly to
one form of enantiomer. However, against E. multilocularis, both en-
antiomers exhibited similar activities (Stadelmann et al., 2011). In the
secondary infection model mice are infected by intraperitoneal in-
oculation of metacestodes, reﬂecting the late chronic, disseminated
stage of disease. In this model we showed that intraperitoneal injection
of meﬂoquine at 25mg/kg twice per week during 8 weeks resulted in a
signiﬁcant reduction of the parasite burden (Küster et al., 2011). The
same was achieved upon oral application of meﬂoquine at 100mg/kg,
twice per week for 12 weeks (Küster et al., 2015). Thus, meﬂoquine was
active in the chronic disease model. However, there is no information
on the drug plasma concentrations required for activity against murine
AE in the above-mentioned studies. Further, meﬂoquine has not yet
been assessed in a primary infection model, i.e. in mice infected orally
with E. multilocularis eggs reﬂecting the natural route of infection and
earlier stage of disease. E. multilocularis ferritin and cystatin were
identiﬁed to possibly interact with meﬂoquine (Küster et al., 2015).
However, this has not been further investigated and additional in-
formation on the mode of action of meﬂoquine against E. multilocularis
is lacking to date.
We here assessed the anti-parasitic eﬀect of meﬂoquine in a primary
mouse infection model of AE, and measured drug plasma concentra-
tions by high-performance liquid chromatography (HPLC). In addition,
ten derivatives of the molecule were tested in vitro against E. multi-
locularis metacestodes to further investigate the mode of action and
structure activity relationship of meﬂoquine.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich (Buchs,
Switzerland), if not stated otherwise.
2.2. Isolation of E. multilocularis eggs and viability assessment
E. multilocularis eggs were obtained from naturally infected foxes
during the regular Swiss hunting season in spring 2017 according to
Hofer et al. (2000). In brief, adult E. multilocularis worms from the small
intestines of foxes were collected and kept in 0.9% NaCl, the worms
were squashed and the suspension was ﬁrst passed through a 105 μm
and a 41 μm diameter mesh, followed by a 21 μm mesh (Lanz-Anliker
Abbreviations
ABZ albendazole
AE alveolar echinococcosis
PGI phosphoglucose isomerase
SH sodium-hypochlorite
TLC thin-layer chromatography
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AG, Switzerland). The suspension was stored at 4 °C in PBS with 100 U
penicillin and 100 μg streptomycin (Life Technologies, Switzerland)
(PBS-P/S). The egg suspension was centrifuged every second to third
week (500×g, 10min, 4 °C), the supernatant was removed and replaced
by fresh PBS-P/S. Integrity (maturity) of Echinococcus eggs was assessed
by sodium hypochlorite resistance test (Deplazes and Eckert, 1988). In
brief, 0.3 mL of a sodium-hypochlorite solution (2% active chlorine, pH
12) was added to 0.4mL E. multilocularis egg suspension (500–1000
eggs/mL). The total number of eggs was determined in a McMaster-
chamber. Few minutes after the addition of sodium-hypochlorite solu-
tion, oncospheres with intact membranes were counted. Sodium hy-
pochlorite resistance was calculated from triplicate counts as percen-
tage of intact oncospheres.
2.3. Animal housing and experimental infection with E. multilocularis eggs
All manipulations with animals followed the guidelines of the Swiss
legislation on experimental animal procedures and the experiment was
approved by the Bernese cantonal authorities under the license number
BE112/14. Eight-week old female BALB/c mice (Charles River,
Sulzfeld, Germany) weighing 20.4 ± 0.8 g at the beginning of the ex-
periment were housed in temperature- and humidity-controlled animal
facilities (biosafety level 2) with day/night cycle (12/12 h) and free
access to water and food. Prior to egg infection, 35 mice were trans-
ferred to a biosafety level 3 animal facility and were infected by oral
gavage of approximately 200 E. multilocularis eggs (corresponding to 46
viable eggs) suspended in 100 μL PBS. An additional 9 female BALB/c
mice received oral gavage of 100 μL PBS only. After two weeks, animals
were transferred back to a conventional biosafety level 2 facility.
2.4. Meﬂoquine treatment
The infected mice were randomly allocated into three egg-infected
groups: (I) meﬂoquine treatment (n = 9); (II) albendazole (ABZ)
treatment (n = 8); (III) placebo treatment (n = 9). Group (IV) consisted
of the non-infected control group (n = 9). Based on power analysis in
G*Power (version 3.1.9.2), a power of 0.8 and a p-value of 0.05, the
minimal group size was calculated to n = 8. In groups I, II, and IV, we
increased this number to n = 9, as for these groups plasma con-
centration assessments in three times three animals were planned (see
section 2.7). At 4 weeks post infection (p.i.) mice were treated for a
period of 12 weeks by oral gavage with drugs suspended in 100 μL corn
oil. Meﬂoquine (Selleckchem, LuBioScience, Luzern, Switzerland) was
applied at 100mg/kg twice a week, and ABZ at 200mg/kg during 5
consecutive days per week. The treatment schedule was as follows:
mice in group (I) received meﬂoquine on day 1 and day 4, and corn oil
without meﬂoquine on days 2, 3 and 5 of each week; to group (II) ABZ
was applied on days 1–5 each week; group (III) received corn oil on
days 1–5 each week; the uninfected mice in group (IV) were treated
with meﬂoquine on day 1 and day 4, and with corn oil only on days 2,
3, and 5 of each week (as in group (I)), in order to evaluate meﬂoquine
pharmacokinetics in uninfected mice. No treatments were performed on
days 6 and 7 of each week. After 12 weeks of treatment, all animals
were euthanized by CO2, livers were resected and cut into single liver
lobes. Each liver lobe was placed into a squeeze chamber and presence
of lesions was assessed in a blinded way using a stereo microscope.
Lesion numbers of the three infected groups were analyzed by one-sided
exact Wilcoxon rank-sum test using the R package coin version 1.2.2
(Hothorn et al., 2006) and p-values were Bonferroni adjusted (R version
3.4.2). The signiﬁcance level was set to p < 0.05. Figures were pre-
pared in Microsoft Excel (2010) and Adobe Illustrator 2015.1.0.
2.5. Histopathology
Histopathological analysis of liver tissues was performed from each
mouse. Samples of the left lateral liver lobe were ﬁxed for 24 h in 4%
paraformaldehyde and paraﬃn embedded. Blocks were sectioned and
stained with hematoxylin and eosin. Morphological changes on each
section in relation to the controls were recorded. The microscopical
evaluation was performed in a blinded fashion by a board-certiﬁed
veterinary pathologist.
2.6. E. multilocularis-speciﬁc PCR of mouse livers
The presence or absence of E. multilocularis DNA in livers of infected
mice was assessed by PCR. Each liver was cut into two pieces of similar
size that were then treated equally. DNA was extracted using a com-
mercial kit (NucleoSpin DNA RapidLyse; Macherey-Nagel, Oensingen,
Switzerland). The samples were digested in 720 μL lysis buﬀer and
30 μL Proteinase K solution for 2 h at 65 °C. One glass bead of 5mm in
diameter was added prior to digestion and the samples were homo-
genized just before the start of the digestion and after 1 h of digestion in
a FastPrep 24 Tissue lyser (MP Biomedicals, Eschwege, Germany) at
4m/s for 60 s. DNA extraction was then continued according to the
manufacturer's protocol with 160 μL of the digested samples. The ex-
tracted DNA was subsequently quantiﬁed in triplicates using the
QuantiFluor dsDNA System (Promega, Dübendorf, Switzerland) ac-
cording to the manufacturer's manual. Polymerase chain reaction (PCR)
was performed according to Trachsel et al. (2007) with slight mod-
iﬁcations applying the primers Cest1 and Cest2 (Euroﬁns Genomics,
Ebersberg, Germany) of said study to amplify the mitochondrial NADH
dehydrogenase subunit 1 gene. The ampliﬁcation was done in a ﬁnal
volume of 20 μL reaction mixture (all components except the primers
and samples were purchased from Promega), containing GoTaq Reac-
tion buﬀer, 10mM nucleotide mix, 1 U GoTaq G2 DNA Polymerase,
0.5 μM Cest1 primer, 0.5 μM Cest2 primer, and 1 μL sample. The PCR
reactions were performed in a T3000 Thermocycler (Biometra, Göt-
tingen, Germany) and had an initial denaturation at 94 °C for 3min,
followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at
58 °C for 60 s, and elongation at 72 °C for 60 s, and a ﬁnal elongation at
72 °C for 5min. The PCR products were subsequently visualized in a 2%
agarose gel with 0.2 μg/mL Ethidium bromide (Promega) under an UV
illuminator.
2.7. Blood-sampling and sample extraction
At least 60 μL blood-samples were taken during the 12-week course
of treatment from the tail vein of mice for subsequent analysis of me-
ﬂoquine plasma concentrations. Blood samples were taken 1 and 5
weeks after treatment initiation (after doses 3 and 11 respectively). 12-
week blood samples were taken by heart puncture (after dose 23) after
euthanasia. At each of these time points, blood samples were retrieved
6, 24, and 48 h after meﬂoquine dosage from 3 mice in each group.
Blood was taken with heparin-coated microvette tubes and plasma was
retrieved by centrifugation for 15min, 10′000×g at 4 °C. Each plasma
sample was then spiked with the internal standard quinine (0.1 g/L in
methanol) to 31.25mg/L. All samples were immediately frozen on dry
ice and stored at - 80 °C until analysis by HPLC. At every time point, an
internal standard sample with quinine only was frozen in order to
follow stability of the standard over time.
Plasma extraction and determination of meﬂoquine concentrations
in mouse plasma were largely performed according to Ingram et al.
(2013). For extraction, 1mL acetonitrile was added to each plasma
sample, and after short vortexing, samples were centrifuged at room
temperature for 10min at 10′000×g. Supernatants were collected and
were dried for 2.5 h at 30 °C in an Eppendorf Concentrator 5301. Dried
samples were reconstituted in 110 μL acetonitrile/potassium dihy-
drogen phosphate buﬀer (1:1 mix, potassium dihydrogen phosphate
buﬀer 0.05M, pH 3.9, pH adjusted with 0.05% phosphoric acid). After
centrifugation (13′000×g, 10min at room temperature), samples were
transferred into conical HPLC cuvettes (0.2 mL, 6× 31mm, wide
opening, Macherey Nagel) and were immediately subjected to HPLC.
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2.8. Meﬂoquine standard curve for HPLC
A calibration curve was established by spiking of plasma from non-
treated mice with a 1:2 dilution series of meﬂoquine from 25 to
0.098mg/L (stock in acetonitrile/potassium dihydrogen phosphate),
covering the range of the plasma samples. All calibration samples in-
cluded the internal quinine standard as described above. Three stan-
dard curves were prepared independently. All standard samples were
extracted exactly as stated for the plasma samples above.
2.9. Meﬂoquine plasma concentration measurements by HPLC
HPLC was performed as described previously with adaptations
(Ingram et al., 2013). Meﬂoquine concentrations were analyzed on an
Ultimate 3000 System (Dionex, Reinach, Switzerland) with an EC 250/
4 Nucleodur 100-5 C18ec (Macherey Nagel) and UV detection at
284 nm. The mobile phase consisted of 35% methanol, 25% acetoni-
trile, and 40% potassium dihydrogen phosphate (pH 3.9). Column
temperature was 25 °C, ﬂow rate constant at 1mL/min and each run
was 10min. The recorded peaks were annotated according to the re-
tention times of known standards. Stability of samples was assessed
with the help of the internal quinine standard. Meﬂoquine plasma
concentrations were quantiﬁed based on internal calibration of the
peak area to the internal standard quinine and calculated with a linear
calibration curve in the software Chromeleon Ultimate 3000 (Dionex,
CA, USA) and Microsoft Excel 2010. Further calculations and ﬁgures
were prepared in SigmaPlot Version 14, and in Adobe Illustrator
2015.1.0.
2.10. Pharmacokinetic model
Meﬂoquine concentrations were modeled using a standard two-
compartment pharmacokinetic model with ﬁrst-order absorption. Mean
meﬂoquine concentrations and a mean dose of 2.04mg were used for
calculations. Primary parameters were the absorption rate constant ka,
the apparent clearance after extravascular administration CL/F, the
intercompartment clearance CLd/F, and the apparent volumes of the
central and peripheral compartment V1/F and V2/F. A secondary
parameter was the terminal elimination half-life T½. Expected steady-
state minimum (Cmin) and maximum (Cmax) concentrations were de-
rived by simulating continued meﬂoquine dosing. Pharmacokinetic
calculations were done using Phoenix WinNonlin 7.0 (Certara,
Princeton, NJ, USA) and Figures prepared in Microsoft Excel (2010) and
in Adobe Illustrator 2015.1.0.
2.11. Synthesis of meﬂoquine derivatives
Melting points were determined with a MQAPF-302 Micro Química
apparatus and are uncorrected. NMR spectra were determined using
400 or 500MHz Bruker AC spectrometers using tetramethylsylane as
internal standard. Splitting patterns are as follows: s, singlet; d, duplet;
t, triplet; quin, quintet; m, multiplet; Brl, broad signal. Infrared spectra
were obtained using a Thermo Nicolet 6700 spectrometer. Mass spectra
were recorded on Agilent 122 5532 GC/MS column by electron impact
and high resolution spectra on a Bruker compact-TOF. The progress of
the reactions was monitored by thin-layer chromatography (TLC) on
2.0×6.0 cm aluminum sheets (silica gel 60, HF-254, Merck) with a
thickness of 0.25mm, ultraviolet light irradiation. For column chro-
matography, a Merck silica gel (70–230 mesh) was used. Solvents and
reagents were used without further puriﬁcation.
10 derivatives of meﬂoquine were synthesized to be compared to
meﬂoquine in vitro activity against E. multilocularis. The synthesis of six
of them (PASALR-01-095, PASALR-01-097, MEFLOMETIL-02, PASALR-
01-146, PASALR-01-096, PASALR-01-126) has been described else-
where (see Table 1) (Barbosa-Lima et al., 2017; Lilienkampf et al.,
2009). The other four derivatives were synthesized as described below
and given in scheme in Fig. 1.
2.11.1. 2-(triﬂuoromethyl)quinolin-4-ol 1
Polyphosphoric acid (11.25 g; 5 w/w) was added to an equimolar
solution of aniline (2.25 g; 24.19mmol) and ethyl 4,4,4-tri-
ﬂuoroacetoacetate (3.0 g; 24.19mmol). The reaction mixture was
stirred at 150 °C for 2 h. Reaction completion was monitored by TLC.
The reaction mixture was slowly poured into ice water (500mL) with
vigorous stirring and stirred at room temperature during 30min. The
precipitated solid was ﬁltered, washed with 50mL water and dried in a
vacuum oven for 4 h to get the crude product as white solid. The crude
product (termed phenol 1) was taken as such for the next step without
further puriﬁcation. Melting point (m.p.) 205–207 °C (lit.: 208–210 °C).
Phenol 1 was not tested against E. multilocularis, but was needed for
further synthesis.
2.11.2. 4-Methoxy-2-(triﬂuoromethyl)quinoline (PAMMLR-01-99.2)
The phenol 1 (3.0 g; 14.08mmol) was dissolved in acetone (70mL)
Table 1
List of ten meﬂoquine derivatives and synthesis.
abbreviation full name R1 R2 source
Meﬂoquine (2,8-bis(triﬂuoromethyl)quinolin-4-yl)-piperidin-2-yl-methanol -CF3 -CHOHPip Selleckchem
PASALR-01-095 ethyl 2-((2,8-bis(triﬂuoromethyl)quinolin-4-yl)oxy)acetate -CF3 -OCH2CO2Et Acros Organics, according to (Lilienkampf et al., 2009)
PAMMLR-01-99.2 4-methoxy-2-(triﬂuoromethyl)quinoline -H -OCH3 2, Fig. 1
PASALR-01-097 N1-(2,8-bis(triﬂuoromethyl)quinolin-4-yl)ethane-1,2-diamine -CF3 -NHCH2CH2NH2 (Barbosa-Lima et al., 2017)
MEFLOMETIL-02 4-methoxy-2,8-bis(triﬂuoromethyl)quinoline -CF3 -OCH3 (Barbosa-Lima et al., 2017)
PASALR-01-137 4-ethoxy-2-(triﬂuoromethyl)quinoline -H -OEt 3, Fig. 1
PASALR-01-146 N-(2-chloroethyl)-2,8-bis(triﬂuoromethyl)quinolin-4-amine -CF3 -NHCH2CH2Cl (Barbosa-Lima et al., 2017)
PAMMLR-01-102-2 2-((2-(triﬂuoromethyl)quinolin-4-yl)amino)ethanol -H -NHCH2CH2OH 4, Fig. 1
PASALR-01-144 N-(2-chloroethyl)-2-(triﬂuoromethyl)quinolin-4-amine -H -NHCH2CH2Cl 5, Fig. 1
PASALR-01-096 N-butyl-2,8-bis(triﬂuoromethyl)quinolin-4-amine -CF3 -NHbutyl (Barbosa-Lima et al., 2017)
PASALR-01-126 2-((2,8-bis(triﬂuoromethyl)quinolin-4-yl)amino)ethanol -CF3 -NHCH2CH2OH (Barbosa-Lima et al., 2017)
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by stirring at room temperature. K2CO3 (6 eq. (11.66) g, 84.48mmol)
and methyl iodide (5 eq., 4.3 mL, 70.4 mmol) were then added. The
reaction was stirred overnight at room temperature. Then, the solvent
was removed under reduced pressure and 70mL water was added. The
aqueous phase was extracted with ethyl acetate (3× 60mL) and the
combined organic phases were dried over anhydrous Na2SO4 and
concentrated under reduced pressure to leave a solid. This was puriﬁed
by ﬂash chromatography (SiO2, 230–400 mesh, AcOEt/nHex 5–10%) to
furnish the compound 4-methoxy-2-(triﬂuoromethyl)quinoline (com-
pound 2 in Fig. 1) as a pale white solid in 70% yield. m. p.: 99–103 °C.
1H NMR (MeOD, 500MHz)δ: 8.27 (1H, d, J=8.5 Hz), 8.08 (1H, d,
J=8.5 Hz), 7.85 (1H, t, J=7.3 Hz), 7.67 (1H, t, J=7.3 Hz), 7.28 (1H,
s), 4.17 (3H, s, -OCH3). 13C NMR (MeOD, 125MHz) d: 164.47, 148.83
(CF3, J=34Hz), 147.72, 131.95, 131.00, 128.42, 127.49, 121.63,
121.54, 96.08, 55.83. (IR v cm−1: 1315 (C-O-C). Theoretical mass
calculated for [C11H8F3NO + H]: 228.0636; Found: 228.0634.
2.11.3. 4-Ethoxy-2-(triﬂuoromethyl)quinoline (PASALR-01-137)
The phenol 1 (3.0 g; 14.08mmol) was dissolved in acetone (70mL)
by stirring at room temperature. K2CO3 (6 eq. (11.66) g, 84.48mmol)
and ethyl bromide (5 eq., 5.2 mL, 70.4mmol) was added. The reaction
was stirred overnight. Then, the solvent was removed under reduced
pressure and 70mL water was added. The aqueous phase was extracted
with ethyl acetate (3×60mL) and the combined organic phases were
dried over anhydrous Na2SO4 and concentrated under reduced pressure
to leave a solid which was puriﬁed by trituration in hot n-Hexane. The
compound 4-ethoxy-2-(triﬂuoromethyl)quinoline (compound 3 in
Fig. 1) was a pale white solid with 55% yield. m. p.: 90–92 °C. 1H NMR
(MeOD, 400MHz) δ: 8.29 (1H, d, J=8.5 Hz), 8.07 (1H, d, J=8.5 Hz),
7.84 (1H, t, J=8.5 Hz), 7.67 (1H, t, J=8.5 Hz), 7.25 (1H, s), 4.42 (2H,
q, O-CH2CH3, J=4Hz), 1.60 (t, 3H, CH3, J=4Hz). 13C NMR (MeOD,
125MHz) δ: 165.08, 150.23 (CF3, J=34Hz), 149.22, 132.40, 129.82,
128.84, 123.15, 123.02, 121.54, 97.96, 66.55, 14.65. IR v cm−1: 1340
(C-O-C). Theoretical mass calculated for [C12H10F3NO + H]:
242.0793; Found: 228.0785.
2.11.4. 2-((2-(triﬂuoromethyl)quinolin-4-yl)amino)ethanol (PAMMLR-
01-102-2)
A mixture of compound 3 (500mg, 2.371mmol) and 5mL of
ethanolamine was heated to 130 °C under stirring for 4 h when TLC
analyses indicated total consumption of the starting material. Water
(15mL) was added to the reaction mixture and it was extracted with
ethyl acetate (3× 25mL). The organic phase was dried and evaporated
under reduced pressure to yield an oil which was submitted at chro-
matographic puriﬁcation on silica gel (SiO2, 70–230 mesh, MeOH/
CHCl3 10%). The product 2-((2-(triﬂuoromethyl)quinolin-4-yl)amino)
ethanol (compound 4 in Fig. 1) was obtained at 62% according to
(Halby et al., 2017). m. p.: 173–175 °C.
2.11.5. N-(2-chloroethyl)-2-(triﬂuoromethyl)quinolin-4-amine (PASALR-
01-144)
0.3mL of SOCl2 was added to a solution of compound 4 (200mg;
0.78mmol) in 10mL of CH2Cl2. After 2 h of reaction at reﬂux, TLC
indicated a total consumption of the starting material. 10% NaOH so-
lution (20mL) was slowly added and extracted with ethyl acetate
(3×20mL). The organic phase was dried with Na2SO4 and evaporated
for yield a residue which was submitted to chromatographic puriﬁca-
tion on silica gel (SiO2, 70–230 mesh, AcOEt/nHex 20%). The product
N-(2-chloroethyl)-2-(triﬂuoromethyl)quinolin-4-amine (compound 5 in
Fig. 1) was obtained in 75% yield according to (Halby et al., 2017). m.
p.: 78–80 °C.
2.12. In vitro testing of meﬂoquine derivatives against E. multilocularis
metacestodes
In vitro culture of E. multilocularis (isolate H95) metacestodes in co-
culture with Reuber rat hepatoma cells was performed as described
previously (Stadelmann et al., 2010). All compounds were prepared as
20mM stocks in DMSO. The metacestode vesicle damage was assessed
by phosphoglucose isomerase (PGI) assay as described previously
(Stadelmann et al., 2010). In short, in vitro cultured metacestode ve-
sicles of approximately 4mm in size were extensively washed in PBS
and taken up in an equal volume of DMEM without phenol red (Bios-
wisstec, Schaﬀhausen, Switzerland), including penicillin/streptomycin
(100 U/mL, Thermo Fisher Scientiﬁc, Zug, Switzerland). Parasites were
distributed into a 48 well-plate at 1mL per well and meﬂoquine or
derivatives were added to a ﬁnal concentration of 10, 20, 30, and
40 μM. 0.1% Tx-100 served as a positive control, DMSO only as a sol-
vent control. Samples were prepared in triplicates. PGI-assays were
carried out after 5 and 12 days (Stadelmann et al., 2010). Active me-
ﬂoquine derivatives were further tested at concentrations ranging from
40 to 1.25 μM in a 1:2 serial dilution and parasite damage by PGI-assay
was assessed as described previously (Stadelmann et al., 2010). Cal-
culations were performed in Microsoft Excel (2010), and ﬁnal ﬁgures
Fig. 1. Synthesis of meﬂoquine derivatives based on the C-4 position.
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were prepared in Adobe Illustrator 2015.1.0.
3. Results
3.1. Meﬂoquine treatment is eﬃcacious in mice orally infected with E.
multilocularis eggs
Upon isolation of E. multilocularis eggs from fox intestines, sodium
hypochlorite resistance test showed that egg maturity was 23 %. All
mice received a dose of approximately 200 eggs. Four weeks p. i., the
26 egg-infected mice (groups I, II, and III), as well as the non-infected
mice (group IV) underwent treatment for 12 weeks. No adverse eﬀects
were observed in any of the animals. Thereafter, all animals were eu-
thanized. The number of liver lesions was assessed by stereo micro-
scopical examination in a squeeze chamber (Fig. 2A), histological ex-
amination of each left lateral liver lobe was carried out by a pathologist,
and infection of the liver tissue was conﬁrmed by PCR (Fig. 2B,
Supplementary Table 1). The blinded stereo microscopical examination
of control group samples (group III, Fig. 2A) revealed the presence of E.
multilocularis lesions in 5 of 9 mice. In ABZ-treated mice (group II),
lesions were observed in 3 out of 8 mice, which was not signiﬁcantly
diﬀerent from the placebo group (p=0.591). In the meﬂoquine-treated
group (group I), only 1 out of 9 mice exhibited a parasite lesion in the
liver, and compared to the placebo group, the diﬀerence was statisti-
cally signiﬁcant (p=0.044) (Fig. 2A). However, compared to the ABZ-
treated mice, meﬂoquine treatment did not lead to a signiﬁcant im-
provement (p= 0.406). Histopathological examination of liver sections
identiﬁed two animals (one each in the meﬂoquine treatment group (I)
and the control group (III)) with E. multilocularis metacestodes and as-
sociated inﬂammation. Another two animals from the ABZ group had
inﬂammatory lesions that could originate from parasite infection, but
metacestode tissue was not clearly discernible. No further histopatho-
logical changes were detected in the liver tissue of other animals. PCR
of whole livers conﬁrmed the presence/absence of E. multilocularis le-
sions in those tissue samples previously identiﬁed by stereo microscopy
(Fig. 2B, Supplementary Table 1).
3.2. Meﬂoquine plasma concentrations of infected and control-mice are
similar
During the 12 weeks meﬂoquine-treatment, meﬂoquine plasma
concentrations were periodically assessed by HPLC in E. multilocularis-
infected and corresponding non-infected animals at weeks 2, 6, and 12
of treatment. A representative HPLC chromatogram is shown in
Supplementary Fig. 1. As depicted in Fig. 3A, no diﬀerence in me-
ﬂoquine plasma concentrations was observed between non-infected and
infected animals. There was a gradual decrease of meﬂoquine con-
centrations after dosing, with peak levels at 6 h and lowest levels
measured after 48 h (Fig. 3A). At 6 h post-dosage, meﬂoquine con-
centrations reached an average (± SD) between 1.58 (± 0.11) and
2.65 (± 0.53) mg/L, whereas after 24 h they dropped to 0.94 (± 0.07)
to 2.05 (± 0.25) mg/L, and after 48 h to 0.57 (± 0.16) to 1.37
(± 0.15) mg/L. With increasing treatment-time, meﬂoquine con-
centrations accumulated slightly (Fig. 3A).
The limited number of blood samples that could be drawn from a
single mouse did not allow for individual pharmacokinetic calculations.
However, to get a more comprehensive picture on the evolution of
meﬂoquine concentrations, a pharmacokinetic analysis using average
concentrations was performed (Fig. 3B). Parameter estimates were
ka= 0.3 h−1, CL/F= 0.014 L/h, CLd/F=0.027 L/h, V1/F=1.04 L,
V2/F= 7.39 L. The terminal half-life of meﬂoquine was calculated as
580 h. After 12 weeks of treatment, the predicted steady-state trough
level (Cmin 1.15mg/L) was reached to 91.4% and the predicted steady-
state peak level (Cmax 2.63mg/L) was reached to 96.6%.
3.3. In vitro activity of meﬂoquine derivatives against E. multilocularis
metacestodes
Currently, there is no information available on which structural
entities of meﬂoquine are important for the observed eﬀects against E.
multilocularis. The in vitro activities of 10 structural meﬂoquine deri-
vatives against E. multilocularis metacestodes were assessed by PGI-
assay. As shown in Fig. 4A, meﬂoquine was the most potent drug at
concentrations above 20 μM, as it induced the strongest PGI-release
after 5 and 12 days of treatment. Five derivatives (PASALR-01-097,
PASALR-01-146, PASALR-01-144, PASALR-01-096, and PASALR-01-
126) also exhibited in vitro activity by PGI-assay. With the exception of
PASALR-01-144, which was the least active of these compounds, all
other active derivatives contain a triﬂuoromethyl-group in the R1 re-
sidue (position 8 of the quinoline, see Figs. 1 and 4B). In addition, the
R2 residue (2-piperidylmethanol substitution, see Figs. 1 and 4B) of the
above-mentioned active compounds contains at least one amino group
in the substitution. For none of the tested compounds did an extended
incubation period of 12 days lead to much higher anti-parasitic activity,
except for PASALR-01-096. At concentrations lower than 10 μM, none
of the active compounds exhibited any activity against in vitro cultured
E. multilocularis metacestodes.
Fig. 2. Meﬂoquine treatment of Echinococcus multilocularis egg-infected
mice. BALB/c mice, orally infected with E. multilocularis eggs, were treated by
either meﬂoquine (100mg/kg twice per week, n=9), ABZ (200mg/kg, 5 times
per week, n= 8) or control-treated (placebo, n= 9). After 12 weeks of treat-
ment, parasite lesion numbers in the liver were assessed microscopically (A)
and presence or absence of lesions in whole liver extracts was conﬁrmed by PCR
(B, see also Supplementary Table 1). A representative agarose gel is shown in
(B) with 1, positive control; 2, negative control; 3, extract from infected mouse;
4, extract from non-infected mouse; L, 100 bp ladder.
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4. Discussion
Over the past years, the anti-malarial drug meﬂoquine has been
repurposed against a variety of infectious agents (Kunin and Ellis, 2000;
Keiser and Utzinger, 2012; Rodrigues-Junior et al., 2016;
Balasubramanian et al., 2017), and in vivo eﬃcacy of meﬂoquine
against secondary AE, induced by intraperitoneal injection of E. multi-
locularis metacestodes into mice, has been well documented (Küster
et al., 2011, 2015; Gorgas et al., 2017). In this study, we have assessed
the eﬃcacy of meﬂoquine treatment against primary AE, caused by oral
infection with E. multilocularis eggs, where the site of infection reﬂects
the situation in humans. Mice were treated bi-weekly by oral gavage of
100mg/kg meﬂoquine. This dose had previously been determined to be
the optimal dosage against secondary murine AE in terms of achieving
eﬃcacy versus preventing adverse side eﬀects (Küster et al., 2015).
However, in those studies the plasma levels achieved by this treatment
in infected and non-infected BALB/c mice were not analyzed. We here
provide corresponding information and present measurements of
plasma levels in weeks 2, 6, and 12 of treatment, with plasma samples
obtained at 6, 24, and 48 h post-drug application. Peak-levels were
expected to occur around 6–8 h after dosage based on previous studies
in rodents (Ingram et al., 2013; McCarthy et al., 2016). As expected, a
slight accumulation of meﬂoquine plasma over time was observed.
Overall, meﬂoquine plasma levels were similar in egg-infected versus
non-infected mice. This contrasts with Schistosoma-infected mice, where
meﬂoquine concentrations and half-lives diﬀered when compared to
healthy control mice (Ingram et al., 2013).
In a pharmacokinetic model based on the observed meﬂoquine-le-
vels, steady-state levels were predicted to be 1.15mg/L for Cmin and
2.63mg/L for Cmax, and steady-state was reached to 91.4% and 96.6%,
respectively, after 12 weeks of treatment, suggesting that concentra-
tions below the predicted steady-state concentrations might be eﬀec-
tive. In humans, the average steady-state levels after 13 weeks of a
prophylactic weekly meﬂoquine-dosage of 250mg meﬂoquine was Cmax
1.74 (± 0.34) mg/L and Cmin 1.14 (± 0.34) mg/L in one study (Pennie
et al., 1993) and Cmax 1.68 (± 0.24) mg/L and Cmin 1.12 (± 0.29) mg/
L in a diﬀerent study (Gimenez et al., 1994). Another publication,
which covered a treatment period of 21 weeks, reported steady-state
levels of 0.56–1.25mg/L (Mimica et al., 1983). Overall, the expected
meﬂoquine concentrations in humans receiving a prophylactic weekly
dosage of 250mg meﬂoquine range between 0.5 and 1.7mg/L and are
thus similar, but slightly lower, to concentrations reached in mice in
this study. The estimated half-life of meﬂoquine in mice was 580 h in
this study, which corresponds closely to half-lives described for me-
ﬂoquine in humans after weekly dosage for 13 weeks (422 ± 9 h
(Pennie et al., 1993), or 421 ± 157 h, (Gimenez et al., 1994).
The major drawback of meﬂoquine are the described adverse side-
eﬀects, in particular neuropsychiatric syndrome (OR=3.92), which
includes confusion and disorientation (23.2%), dementia and amnesia
(7.2%), and seizures (7.8%), as well as prodromal symptoms such as
anxiety (11.3%), depression (17.4%), sleep disturbance (23.3%), and
other neurological symptoms (Nevin and Leoutsakos, 2017). Serious
side-eﬀects were observed in 0.9% and 1% of meﬂoquine-medicated
malaria patients when compared to treatment with doxycycline or
atovaquone-proguanil respectively, and more detailed information on
the frequency of side-eﬀects is given in a recent Cochrane review
(Tickell-Painter et al., 2017). Various biological pathways have been
suggested to be involved in these neuropsychological side-eﬀects
(Gamo et al., 2010). One of them is post-hepatic syndrome, which leads
to release of toxic levels of retinoids into the body, and thereby toxic
neurological symptoms (Mawson, 2013). Adverse eﬀects were also
described to occur with co-medications that interfere with metabolism
in the liver, as well as alcohol (Croft and Herxheimer, 2002). For these
reasons, meﬂoquine-prophylaxis for travelers to malaria-endemic
countries is not recommended for patients with a previous history of
psychological disorders or alcohol abuse (Tickell-Painter et al., 2017).
The advantages of meﬂoquine, which is still clinically applied, are the
activity against chloroquine-resistant malaria, the long half-life re-
sulting in better patient-compliance, as well as safety of use in preg-
nancy (Dassonville-Klimpt et al., 2011).
In mice treated with meﬂoquine, only one mouse out of nine had
one single E. multilocularis lesion whereas in mice without treatment
ﬁve out of nine had multiple lesions. The egg-infection model of murine
AE is not as well developed as the secondary murine model of AE, and
up to date assessments of parasite burden at the endpoint have relied
solely on morphological observation of parasite lesions in squeezed li-
vers by stereo microscopy. In this study, we have applied an additional
and more objective assessment, by using whole-liver PCR based on the
method described by Trachsel and colleagues (Trachsel et al., 2007).
PCR detected parasite DNA in whole liver extracts only in those samples
that were identiﬁed to contain E. multilocularis lesions by microscopy,
thus validating the microscopy results. For the future, this method
could even be expanded for a quantitative assessment of the parasite
Fig. 3. Meﬂoquine plasma concentrations in BALB/c mice. (A) Animals
were treated with 100mg/kg meﬂoquine per os twice per week. Plasma con-
centrations as assessed by HPLC are given for weeks 2, 6 and 12 of treatment. At
these intervals, plasma concentrations were measured 6, 24 and 48 h after
dosing (n=3 for each time point). (B) Modeling of meﬂoquine concentrations
as measured in (A) based on a standard two-compartment pharmacokinetic
model with ﬁrst-order adsorption. Predicted values are shown as solid line.
Empty circles show observed meﬂoquine concentrations.
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burden. Serology could be applied as an alternative method to conﬁrm
successful infection. However, as of to date, the Em2-based serology
classically applied for human patients exhibited varying sensitivity in
egg-infected mice (own observations). This is as also the case in dogs
with AE, where sensitivity of Em2-serology ranges between 0.52 and
0.92 (Frey et al., 2017). Thus, for the murine model of primary infec-
tion with E. multilocularis, a better diagnostic antigen awaits to be de-
ﬁned.
To date, little is known regarding the mode of action of meﬂoquine
against E. multilocularis. As the parasite does not rely on blood con-
sumption, the accepted mode of action involving accumulation of toxic
heme can be excluded. A deeper understanding of the structural entities
that cause the profound anti-echinococcal activity, as well as of the
molecular drug target(s), is needed to improve the eﬃcacy and safety-
proﬁle of meﬂoquine. In vitro eﬃcacy studies on 10 meﬂoquine-deri-
vatives against E. multilocularis metacestodes showed that the tri-
ﬂuoromethyl group of meﬂoquine at the R1 position (position 8 of the
quinoline structure) seems to be essential, as it is described against
Plasmodium spp. (Dassonville-Klimpt et al., 2011). The other tri-
ﬂuoromethyl group (on position 2 of the quinoline structure) is also
known to be essential for the potent activity against malaria
(Dassonville-Klimpt et al., 2011), but this residue was not further as-
sessed in the present study. Binding of metal ions to the triﬂuoromethyl
groups could contribute to the mechanism of action, since the iron-
binding protein ferritin was shown to bind to meﬂoquine in E. multi-
locularis (Küster et al., 2015). Furthermore, meﬂoquine inhibits hemo-
zoin formation from the heme of the metalloprotein haemoglobin in
Plasmodium spp. (Egan et al., 1994), as well as the magnesium-con-
taining enolase of Schistosoma mansoni (Manneck et al., 2012). Upon
substitution of the 2-piperidylmethanol group at the R2 position, the
derivative was only active when an amino group was present. A similar
observation was made by Barbosa-Lima et al. who tested 2,8-bis(tri-
ﬂuoromethyl)quinoline analogs against the Zika virus (Barbosa-Lima
et al., 2017). For anti-malarial activity, the amino group in R2 is known
to be essential, as is the hydroxyl group (Dassonville-Klimpt et al.,
2011). According to our observations, the hydroxyl group does not play
an essential role for anti-echinococcal activity. Within the limited
number of derivatives tested here, we could show that a more electron-
withdrawing substituent on the beta-position of the amine in the R2
resulted in higher activity against E. multilocularis metacestodes.
5. Conclusions
We here provide ﬁrst evidence that bi-weekly meﬂoquine treatment
in mice infected orally with E. multilocularis eggs at 100mg/kg, is at
least as active as 200mg/kg ABZ applied 5 days per week. In the pre-
sent study, analytical assessment of plasma levels showed that oral
application of meﬂoquine by gavage led to plasma levels that are
slightly above the described levels reached in humans taking the
compound for malaria prophylaxis. Thus, there is a promising oppor-
tunity that potentially might be exploited also for the treatment of
human AE. This could be of particular interest for patients that suﬀer
from severe benzimidazole toxicity. However, due to the inherent
variability of the biological material used for such infections in this
model, and the limited numbers of mice that got successfully infected,
further conﬁrmatory studies need to be carried out in the future. In vitro
structure-activity relationship studies show that the eﬃcacy of me-
ﬂoquine is highly dependent on the presence of two residues, both of
which are also essential for its anti-malarial activity. Further studies
will be needed to elucidate the precise mode of action of meﬂoquine
against E. multilocularis.
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